Semaglutide: Evidence Before Hype
Semaglutide is a GLP-1 receptor agonist with substantial clinical evidence across obesity, type 2 diabetes, cardiovascular risk reduction, chronic kidney disease, and other metabolic conditions.
The Founder’s Institute of Medicine & Education Semaglutide Peptide Intelligence Monograph examines the evidence behind its approved uses, emerging applications, safety profile, and the growing marketplace of compounded and non-approved products.
Inside the monograph:
• Compound identity and GLP-1 receptor pharmacology
• FDA-approved semaglutide products and indications
• Obesity and weight-management evidence
• Type 2 diabetes and glycemic outcomes
• Cardiovascular outcomes from SELECT and SOUL
• Kidney outcomes from the FLOW trial
• MASH and liver-related evidence
• Safety, tolerability, and important adverse effects
• Body-composition and weight-regain considerations
• Compounded and non-approved semaglutide risks
• Claim-by-claim FIPES evidence assessment
• Fully referenced scientific literature
Institute Bottom Line: Semaglutide has one of the strongest human evidence bases in the modern peptide and incretin landscape. Its benefits are well established for several approved indications, but those findings should remain clearly separated from unsupported claims, inappropriate extrapolation, and risks associated with non-approved products.
Version 1.0 | Evidence cutoff: August 25, 2026
Educational scientific evidence review. Not medical advice, a treatment protocol, prescription, or promotional claim.
This publication is provided solely for educational and informational purposes. It does not constitute medical advice, diagnosis, prescribing guidance, or a recommendation for individual treatment. It is not intended to replace evaluation, consultation, or treatment by a qualified healthcare professional. Treatment decisions must be based on the individual patient's circumstances and made in consultation with an appropriately licesnsed healthcare professional.